about
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara studyCarfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaA randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialPrognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaCarfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyBortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyDifferentiation stage of myeloma plasma cells: biological and clinical significance.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.A new prognostic score for AIDS-related lymphomas in the rituximab-era.Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable diseaseCytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaCarfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyAcute lymphoblastic leukemia in adolescents and young adults.Multiple myeloma with extramedullary disease.A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsLenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
P50
Q28296718-2C1FA0EB-DB5D-476E-B850-850A200C705DQ30595175-D6AC319F-0388-40A2-A8DA-323D87CE5384Q31136560-51B3A5A4-FAF7-4A8A-A565-7B57998B2E14Q33376498-1C4FDD01-5EA4-4DAF-87D8-A2CEDF2B078CQ33389982-B4AA16A8-599D-4AC5-899E-6D9E9F7A4388Q33401766-BBF9128E-456F-41DC-8BA9-9DCA187E2277Q33410172-D3B5E56A-5E5C-4B54-A696-F3ECEF6BEB34Q33424306-4FC85D91-ACB0-42EC-B713-0DE89FDA1B53Q33428423-0398BA5D-0A83-4E75-B14D-936110E7BEECQ33428556-4D816B77-E89E-4246-BDF4-5DD1BFBF9C92Q33432492-1B2F6714-B865-4BB1-8718-B03ED570E24FQ33433893-9680B392-C07B-423B-9130-677B6C9943A2Q33435789-8BA17ED4-B6DD-4946-8681-8701D4CC428FQ33437577-F6815AB2-1EE4-4149-A041-E4D420670CA9Q33437811-D6D37B24-FC09-4043-955D-4C773F724BA5Q33441845-8659BF5A-A33E-4C22-B503-44061EFEB3A6Q33587563-6CEBD0DC-0940-4AF3-A370-DD5449622FDCQ33621587-44FE907B-8B75-4373-A111-C171823D9A0CQ33626064-B7467203-6EFE-4D3C-9F10-8A8AA271821EQ33696008-3CADD0C7-2F20-4825-A898-5A2D2464735CQ33712516-65835D03-BCB6-4DC9-A47E-BEEFA1EB2D0BQ33785935-75529EF7-BF3E-4ACB-A4EB-F261A00AD347Q33978937-D9E4B6F5-0F0C-4A8F-8E6E-C9EA52DA964BQ34255145-93C9C3D0-93FD-4AA0-AC46-41FEEA37F277Q34463597-29F4AC95-D140-4AD3-A30A-787D87472598Q35944707-CC1B23E2-EDF7-4503-A716-1E800A33DECAQ36115674-3AD69798-8485-4D4D-A49E-357B193FBFB5Q36115680-9CA8D0B5-A09E-4037-965E-67AFED4ADFDEQ36708998-2FD28C0A-EA81-450F-B4D8-B7B717804A8EQ37216472-68C17B18-C2F3-4D89-8339-D6B03289068EQ37228327-74FE38F6-4EAF-4E80-94F6-7DEDEEB20F82Q37291598-BD3EC00C-DADF-4E71-B21E-C25B62BEF9F4Q37570630-557A8D49-3D82-441D-B3E5-5B65864BF1E9Q37613884-E2870BEC-1C48-459B-BDA0-7C29C85144F9Q37959307-1FC7B283-B2FB-4969-98E6-845A80851486Q38411566-2F96F8E7-66A6-49A3-8846-4639D17335D4Q38789282-9C459383-0D63-4DCE-AC3E-A3D1F73E0D36Q38842962-9E007E75-99C8-46DC-9AEE-F30460D1FC83Q39416134-3852C636-5240-4457-AB58-08CD58A1E8D8Q39584752-B18A6080-BA89-46D8-85F5-4732F02CC1CB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Albert Oriol
@ast
Albert Oriol
@en
Albert Oriol
@es
Albert Oriol
@nl
Albert Oriol
@sl
type
label
Albert Oriol
@ast
Albert Oriol
@en
Albert Oriol
@es
Albert Oriol
@nl
Albert Oriol
@sl
prefLabel
Albert Oriol
@ast
Albert Oriol
@en
Albert Oriol
@es
Albert Oriol
@nl
Albert Oriol
@sl
P1053
K-9923-2017
P106
P1153
7006616023
P21
P31
P3829
P496
0000-0001-6804-2221